Sunhawk Vision Biotech, Inc.

As of June 30, 2026, Sunhawk Vision Biotech, Inc. carries a market capitalization of 2.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sunhawk Vision Biotech, Inc. has 70.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sunhawk Vision Biotech, Inc. maintains a current ratio of 13.57, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Sunhawk Vision Biotech, Inc.'s stock has declined approximately 15.52% over the past 52 weeks. The 50-day moving average sits at 39.07, while the 200-day moving average is 39.78.

As of June 30, 2026, Sunhawk Vision Biotech, Inc. holds 349.82M in cash and equivalents against 3.35M in total debt, resulting in a net debt position of -349.82M. Total book value stands at 417.89M, with working capital of 341.23M providing operational flexibility.